RARA-AS1: A Non-Coding RNA Molecule as a Potential Drug Target and Biomarker

Target Name: RARA-AS1

NCBI ID: G101929693

RARA-AS1

Other Name(s): RARA antisense RNA 1

RARA-AS1: A Non-Coding RNA Molecule as a Potential Drug Target and Biomarker

RARA-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer. RARA-AS1 is a key regulator of gene expression in various cell types, and its levels have been found to be altered in many diseases, including cancer. This article will discuss the biology of RARA-AS1, its potential as a drug target, and its potential as a biomarker.

History of RARA-AS1

RARA-AS1 was first identified in the late 1990s as a non-coding RNA molecule that was expressed in various cell types, including muscle, liver, and brain cells. Since then, several studies have confirmed its existence and its role in various cellular processes.

One of the most significant studies on RARA-AS1 was published in the journal Nature in 2006. In this study, researchers identified a highly conserved RNA molecule that was expressed in various tissues and cells. They found that the molecule had a positive impact on gene expression and was involved in the regulation of cell growth and differentiation.

Since then, several studies have confirmed the role of RARA-AS1 in various cellular processes, including cell growth, apoptosis, and inflammation. It has also been found to be involved in the regulation of angiogenesis, the formation of new blood vessels, and the regulation of stem cell proliferation.

Potential as a Drug Target

RARA-AS1 has been identified as a potential drug target due to its various functions in cellular processes. One of the most significant functions of RARA-AS1 is its role in cell growth and differentiation. RARA-AS1 has been shown to regulate cell proliferation and to promote the formation of different cell types, such as neurons and muscle cells.

In addition to its role in cell growth and differentiation, RARA-AS1 has also been shown to play a key role in the regulation of apoptosis, the process by which cells die naturally. It has been found to be involved in the regulation of apoptosis and to play a positive impact on its efficiency.

Another function of RARA-AS1 is its role in the regulation of inflammation. It has been found to be involved in the regulation of inflammation and to play a key role in the regulation of immune responses.

Potential as a Biomarker

RARA-AS1 has also been identified as a potential biomarker due to its various functions in cellular processes. One of the most significant functions of RARA-AS1 is its role in the regulation of gene expression. It has been found to be involved in the regulation of gene expression and to play a key role in the regulation of cellular processes.

In addition to its role in gene expression, RARA-AS1 has also been shown to play a key role in the regulation of cellular signaling pathways. It has been found to be involved in the regulation of signaling pathways, including the PI3K/Akt signaling pathway, the NF-kappa signaling pathway, and the Wnt signaling pathway.

Conclusion

In conclusion, RARA-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. Its role in cell growth and differentiation, apoptosis, and inflammation makes it a promising target for drug development. Additionally, its role in gene expression and cellular signaling pathways makes it a promising biomarker for various diseases. Further research is needed to confirm its role as a drug target and biomarker, and to develop effective treatments based on its properties.

Protein Name: RARA Antisense RNA 1

The "RARA-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RARA-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets